Although currently there is not enough evidence demonstrating the role of [68Ga]Ga-Pentixafor in cervical cancer, CXCR4-PET imaging could potentially be used for prognostication and patient selection for CXCR4-targeting therapies. This evidence concerns the gene CXCR4 and cervical carcinoma.